{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:15:53Z","timestamp":1785194153925,"version":"3.55.0"},"reference-count":56,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background: Excessive intake of fructose, glucose and alcohol is associated with the development of non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). At the same time, these dietetic factors create an environment favorable for the generation of advanced glycation end-products. For this reason, advanced glycation end-products (AGEs) are hypothesized to play role in the development of NAFLD and ALD. In this systematic review and meta-analysis, we explore the relationship between NAFLD and ALD with AGE levels, including their diagnostic accuracy. Methods: The systematic review and meta-analysis has been pre-registered with PROSPERO (CRD42021240954) and was performed in accordance with the PRISMA guidelines. Meta-analyses were performed using the meta R package. Results: We have obtained 11 studies meeting our inclusion criteria, reporting data on 1844 participants (909 with NAFLD, 169 with ALD and 766 healthy controls). NAFLD was associated with significantly higher AGE fluorescence and serum N-(carboxyethyl)lysine (CEL) levels. Patients with alcoholic cirrhosis had significantly higher levels of N-(carboxymethyl)lysine (CML). Only individual studies examined AGEs in the context of their diagnostic accuracy. AGE fluorescence distinguished low and moderate steatosis with an AUC of 0.76. The ratio of CML, CEL and pentosidine to a soluble variant of the AGE receptor differentiated patients with NAFLD from healthy controls with high AUC (0.83\u20130.85). Glyceraldehyde-derived AGE separated non-alcoholic fatty liver (NAFL) from non-alcoholic steatohepatitis (NASH) with acceptable performance (AUC 0.78). Conclusions: In conclusion, NAFLD and ALD are associated with significantly higher levels of several AGEs. More research is needed to examine the diagnostic accuracy of AGEs, however individual studies show that AGEs perform well in distinguishing NAFL from NASH.<\/jats:p>","DOI":"10.3390\/nu13103370","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T21:40:30Z","timestamp":1632778830000},"page":"3370","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Advanced Glycation End-Products in Common Non-Infectious Liver Diseases: Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1856-7246","authenticated-orcid":false,"given":"Kamil","family":"Litwinowicz","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Immunochemistry, Wroclaw Medical University, 50-368 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Waszczuk","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Wroclaw Medical University, 50-556 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2206-6591","authenticated-orcid":false,"given":"Andrzej","family":"Gamian","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Mokdad, A.A., Lopez, A.D., Shahraz, S., Lozano, R., Stanaway, J., Murray, C.J.L., and Naghavi, M. (2014). Liver cirrhosis mortality in 187 countries between 1980 and 2010: A systematic analysis. BMC Med., 12.","DOI":"10.1186\/s12916-014-0145-y"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.29546","article-title":"Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study","volume":"67","author":"Allen","year":"2017","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis","volume":"18","author":"Moon","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2016). EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia, 59, 1121\u20131140.","DOI":"10.1007\/s00125-016-3902-y"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/nu5051544","article-title":"Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease","volume":"5","author":"Gaggini","year":"2013","journal-title":"Nutrients"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cld.2013.09.009","article-title":"The Role of Diet and Nutritional Intervention for the Management of Patients with NAFLD","volume":"18","author":"Barrera","year":"2014","journal-title":"Clin. Liver Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1360-0443.2008.02493.x","article-title":"Drinking patterns, dependency and life-time drinking history in alcohol-related liver disease","volume":"104","author":"Hatton","year":"2009","journal-title":"Addiction"},{"key":"ref_9","first-page":"G364","article-title":"Emerging role of circadian clock disruption in alcohol-induced liver disease","volume":"315","author":"Bailey","year":"2018","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.alcohol.2014.08.013","article-title":"Clock genes in human alcohol abuse and comorbid conditions","volume":"49","author":"Partonen","year":"2015","journal-title":"Alcohol"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jhep.2015.03.006","article-title":"Trends in the management and burden of alcoholic liver disease","volume":"62","author":"Mathurin","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/liv.13299","article-title":"The epidemiology of non-alcoholic fatty liver disease","volume":"37","author":"Bellentani","year":"2017","journal-title":"Liver Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.trsl.2015.08.002","article-title":"Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: Translational and clinical evidence","volume":"167","author":"Federico","year":"2015","journal-title":"Transl. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/acer.12704","article-title":"Alcoholic Liver Disease: The Gut Microbiome and Liver Cross Talk","volume":"39","author":"Hartmann","year":"2015","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3389\/fphys.2019.00423","article-title":"Circadian Clock Genes in the Metabolism of Non-alcoholic Fatty Liver Disease","volume":"10","author":"Shi","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/00952990.2019.1669629","article-title":"Changes in the composition of the human intestinal microbiome in alcohol use disorder: A systematic review","volume":"46","author":"Litwinowicz","year":"2019","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Takeuchi, M., Takino, J.-I., Sakasai-Sakai, A., Takata, T., and Tsutsumi, M. (2017). Toxic AGE (TAGE) Theory for the Pathophysiology of the Onset\/Progression of NAFLD and ALD. Nutrients, 9.","DOI":"10.3390\/nu9060634"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mrgentox.2017.10.005","article-title":"Generation of Advanced Glycation End-Products (AGEs) by glycoxidation mediated by copper and ROS in a human serum albumin (HSA) model peptide: Reaction mechanism and damage in motor neuron cells","volume":"824","author":"Marques","year":"2017","journal-title":"Mutat. Res. Toxicol. Environ. Mutagen."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","article-title":"Advanced glycation end products: Sparking the development of diabetic vascular injury","volume":"114","author":"Goldin","year":"2006","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.17219\/acem\/112612","article-title":"Non-standard AGE4 epitopes that predict polyneuropathy independently of obesity can be detected by slot dot-blot immunoassay","volume":"29","author":"Kuzan","year":"2020","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_22","unstructured":"Litwinowicz, K. (2021, September 23). Advanced Glycation End-Products in Liver Diseases: Meta Analysis. Available online: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=240954."},{"key":"ref_23","unstructured":"Shi, J., Luo, D., Wan, X., Liu, Y., Liu, J., Bian, Z., and Tong, T. (2020). Detecting the skewness of data from the sample size and the five-number summary. arXiv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jrsm.1429","article-title":"Optimally estimating the sample standard deviation from the five-number summary","volume":"11","author":"Shi","year":"2020","journal-title":"Res. Synth. Methods"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2016","journal-title":"Stat. Methods Med. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Schwarzer, G., Carpenter, J.R., and R\u00fccker, G. (2015). Meta-Analysis with R, Springer International Publishing.","DOI":"10.1007\/978-3-319-21416-0"},{"key":"ref_28","unstructured":"R Core Team R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: https:\/\/www.r-project.org."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.17219\/acem\/112611","article-title":"Advanced glycation end products derived from serum albumin modification by glucose (AGE-1) reflect clustering of lipid-associated metabolic abnormalities and are decreased in patients treated with acarbose: A cross-sectional study","volume":"29","author":"Kuzan","year":"2020","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/10715762.2019.1635691","article-title":"Oxidative stress biomarkers in the serum and plasma of patients with non-alcoholic fatty liver disease (NAFLD). Can plasma AGE be a marker of NAFLD? Oxidative stress biomarkers in NAFLD patients","volume":"53","author":"Maciejczyk","year":"2019","journal-title":"Free Radic. Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Mehta, R., Shaw, G., Masschelin, P., Felix, S., Otgonsuren, M., Baranova, A., Goodman, Z., and Younossi, Z. (2018). Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH). PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0199294"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.metabol.2018.01.023","article-title":"Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults","volume":"83","author":"Kontogianni","year":"2018","journal-title":"Metabolism"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jcla.21797","article-title":"Elevation of Serum Levels of Advanced Glycation End Products in Patients with Non-B or Non-C Hepatocellular Carcinoma","volume":"29","author":"Kan","year":"2015","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00210-007-0171-9","article-title":"Unchanged serum levels of advanced glycation endproducts in patients with liver disease","volume":"375","author":"Butscheid","year":"2007","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/j.1440-1746.2007.04943.x","article-title":"Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis","volume":"22","author":"Hyogo","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6289831","DOI":"10.1155\/2019\/6289831","article-title":"Hepatic fat content and liver enzymes are associated with circulating free and protein-bound advanced glycation end products, which are associated with low-grade inflammation: The CODAM study","volume":"2019","author":"Bijnen","year":"2019","journal-title":"J. Diabetes Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1097\/MCG.0000000000000990","article-title":"Modification Patterns of Urinary Albumin Correlates with Serum Albumin and Outcome in Severe Alcoholic Hepatitis","volume":"53","author":"Das","year":"2019","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0168-8278(01)00232-X","article-title":"Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis\u2014Amelioration by liver transplantation","volume":"36","author":"Schinzel","year":"2002","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.clinbiochem.2005.07.016","article-title":"Elevation of N\u03b5-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis","volume":"39","author":"Yagmur","year":"2006","journal-title":"Clin. Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver Operating Characteristic Curve in Diagnostic Test Assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jhep.2011.07.028","article-title":"Endogenous formation of N\u03b5-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis","volume":"56","author":"Gaens","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.str.2011.02.013","article-title":"Advanced Glycation End Product Recognition by the Receptor for AGEs","volume":"19","author":"Xue","year":"2011","journal-title":"Structure"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/rheumatology\/kep199","article-title":"Soluble receptor for advanced glycation end products: A new biomarker in diagnosis and prognosis of chronic inflammatory diseases","volume":"48","author":"Boulanger","year":"2009","journal-title":"Rheumatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2013.07.042","article-title":"Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease","volume":"60","author":"Cusi","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3892\/br.2021.1422","article-title":"Toxicity of advanced glycation end products (Review)","volume":"14","author":"Kuzan","year":"2021","journal-title":"Biomed. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/hep.510300402","article-title":"Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat","volume":"30","author":"Nanji","year":"1999","journal-title":"Hepatology"},{"key":"ref_47","first-page":"1624","article-title":"Signal transductions and nonalcoholic fatty liver: A mini-review","volume":"7","author":"Zeng","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.22578","article-title":"Differential Effects of JNK1 and JNK2 Inhibition on Murine Steatohepatitis and Insulin Resistance","volume":"49","author":"Singh","year":"2014","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/hep.20999","article-title":"JNK1 but not JNK2 promotes the development of steatohepatitis in mice","volume":"43","author":"Schattenberg","year":"2014","journal-title":"Hepatology"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Fernando, D.H., Forbes, J.M., Angus, P.W., and Herath, C.B. (2019). Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205037"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Waqas, K., Chen, J., van der Eerden, B.C.J., Ikram, M.A., Uitterlinden, A.G., Voortman, T., and Zillikens, M.C. (2020). Dietary Advanced Glycation End-Products (dAGEs) Intake and Bone Health: A Cross-Sectional Analysis in the Rotterdam Study. Nutrients, 12.","DOI":"10.3390\/nu12082377"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1073\/pnas.94.12.6474","article-title":"Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy","volume":"94","author":"Koschinsky","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s12276-021-00561-7","article-title":"Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury","volume":"53","author":"Rungratanawanich","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"22194","DOI":"10.1038\/s41598-020-79216-y","article-title":"The impact of low advanced glycation end products diet on obesity and related hormones: A systematic review and meta-analysis","volume":"10","author":"Sohouli","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.3748\/wjg.v22.i35.8026","article-title":"Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease","volume":"22","author":"Leung","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1038\/s41598-021-82585-7","article-title":"The melibiose-derived glycation product mimics a unique epitope present in human and animal tis-sues","volume":"11","author":"Staniszewska","year":"2021","journal-title":"Sci. Rep."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/13\/10\/3370\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:04:58Z","timestamp":1760166298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/13\/10\/3370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":56,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["nu13103370"],"URL":"https:\/\/doi.org\/10.3390\/nu13103370","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]}}}